Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06088498 · ClinicalTrials.gov registry record · Phase 2

App for Reducing Cravings to Smoke

A Phase 2 study of Smoking, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Recruiting
Registry status
Phase 2
Development phase
3,600
Enrollment target
1
Study location

NCT06088498 is a Phase 2 study of Smoking that is actively recruiting participants, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 3,600 participants, above the 426-participant average among 123 other Smoking trials with a reported enrollment target (745% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06088498, a Phase 2 study of Smoking, is actively recruiting participants, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

RECRUITING
Registry status
Phase 2
Development phase
3,600 participants
Enrollment target
1
Study location

Study Summary

The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.

Conditions Studied

Interventions

  • BEHAVIORAL Updating Existing Smartphone App
  • BEHAVIORAL Quitline Services
  • BEHAVIORAL Quitline Services and Smartphone App

Study Locations (1)

Florida

  • Moffitt Cancer Center - Tampa

Trial Details

FieldValue
Enrollment Target 3,600 participants
Start Date 2024-06-11
Est. Completion 2027-05-01
Phase Phase 2

What the Registry Record Tells You About NCT06088498

The ClinicalTrials.gov registry entry for NCT06088498 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 3,600 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 426-participant average among 123 other Smoking trials with a reported enrollment target (745% higher). The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Smoking appearing as the primary indexed condition, and to 3 interventions - of which Updating Existing Smartphone App is the first listed.

NCT06088498 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06088498 about?

NCT06088498 is a clinical study titled "App for Reducing Cravings to Smoke". The overall goal of the study is to assess the efficacy of using cue exposure delivered via a smartphone application as an adjunct to Tobacco Quitline treatment to improve smoking abstinence.

What is the current status of trial NCT06088498?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 3,600 participants. The study started on 2024-06-11. Estimated completion is 2027-05-01.

What conditions does trial NCT06088498 study?

This clinical trial studies the following conditions: Smoking.

What interventions are being tested in trial NCT06088498?

The interventions under investigation include: Updating Existing Smartphone App (BEHAVIORAL), Quitline Services (BEHAVIORAL), Quitline Services and Smartphone App (BEHAVIORAL).

Who is sponsoring clinical trial NCT06088498?

This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06088498 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.